Literature DB >> 10037006

Interdependence between cytokines and cell adhesion molecules to induce interleukin-6 production by stromal cells in myeloma.

X Thomas1, B Anglaret, J P Magaud, J Epstein, E Archimbaud.   

Abstract

Bone marrow (BM) environment is thought to support the growth of myeloma cells and thus to play an important role in the pathogenesis of multiple myeloma (MM). Because interleukin-6 (IL-6) is an essential growth factor in MM, we have examined the effects of two myeloma cell lines (U266 and ARH-77) on the IL-6 production by BM stromal cells in a co-culture system. These cell lines strongly stimulate the IL-6 production and IL-6 triggering was partially dependent on physical contact between lines and stroma. The percentages of cell adhesion to stromal layers were 39% and 25% respectively for ARH77 and U266 cell lines. Inhibition studies with blocking monoclonal antibodies showed the importance of CD49d/CD106 and CD11a/CD54 interactions in the stimulation of IL-6 production by stromal cells. However, cell-to-cell contact was not an absolute requirement for IL-6 production. Cytokines, of which TNF-alpha and IL-1beta produced by MM or accessory cells, were also able to stimulate IL-6 production by fibroblasts and show additive effects. In adhesion assays, TNF-alpha and IL-1beta were able to increase the adhesion of MM cells to stromal cells. CD54 was upregulated by IL-1beta, TNF-alpha or a contact with MM cells while CD106 expression was not, suggesting only a functional change of this molecule. However, the role of monoclonal antibodies, directed against these factors, confirmed the role of TNF-alpha in the IL-6 production by stromal cells, while any IL-1beta intervention was not shown in our co-culture system. IL-6 favoured and maintained adhesion of MM cells to stromal cells spontaneously since its reintroduction in the favoured co-culture system restored their decreased adhesion observed on a glutaraldehyde fixed stromal layer. Overall our data suggest a functional overlap between cytokines and adhesion molecules for the paracrine IL-6 production.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10037006     DOI: 10.3109/10428199809059251

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  10 in total

1.  A galectin-3-dependent pathway upregulates interleukin-6 in the microenvironment of human neuroblastoma.

Authors:  Ayaka M Silverman; Rie Nakata; Hiroyuki Shimada; Richard Sposto; Yves A DeClerck
Journal:  Cancer Res       Date:  2012-03-02       Impact factor: 12.701

Review 2.  Mesenchymal niches of bone marrow in cancer.

Authors:  Ander Abarrategi; Luis Marińas-Pardo; Isabel Mirones; Esther Rincón; Javier García-Castro
Journal:  Clin Transl Oncol       Date:  2011-09       Impact factor: 3.405

3.  Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.

Authors:  Michael S van der Veer; Michel de Weers; Berris van Kessel; Joost M Bakker; Shulamiet Wittebol; Paul W H I Parren; Henk M Lokhorst; Tuna Mutis
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

4.  Cancer stem cell and stromal microenvironment.

Authors:  Li Li; John Cole; David A Margolin
Journal:  Ochsner J       Date:  2013

5.  The protein tyrosine phosphatase CD45 is required for interleukin 6 signaling in U266 myeloma cells.

Authors:  Qun Zhou; Yuan Yao; Solveig G Ericson
Journal:  Int J Hematol       Date:  2004-01       Impact factor: 2.490

Review 6.  Mesenchymal stem cells as a double-edged sword in suppression or progression of solid tumor cells.

Authors:  Fatemeh Norozi; Ahmad Ahmadzadeh; Saeid Shahrabi; Tina Vosoughi; Najmaldin Saki
Journal:  Tumour Biol       Date:  2016-07-20

7.  HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma.

Authors:  Ramadevi Nimmanapalli; Elvira Gerbino; William S Dalton; Varsha Gandhi; Melissa Alsina
Journal:  Br J Haematol       Date:  2008-05-22       Impact factor: 6.998

Review 8.  Mesenchymal stem cells: key players in cancer progression.

Authors:  Sarah M Ridge; Francis J Sullivan; Sharon A Glynn
Journal:  Mol Cancer       Date:  2017-02-01       Impact factor: 27.401

9.  Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells.

Authors:  Barbara Zdzisińska; Agnieszka Bojarska-Junak; Anna Dmoszyńska; Martyna Kandefer-Szerszeń
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-05-30       Impact factor: 4.291

Review 10.  Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death.

Authors:  Magali Castells; Benoît Thibault; Jean-Pierre Delord; Bettina Couderc
Journal:  Int J Mol Sci       Date:  2012-07-30       Impact factor: 6.208

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.